DAVIS, Calif., Dec. 19, 2013 /PRNewswire/ -- Marrone Bio Innovations, Inc. (MBI) (NASDAQ: MBII), a leading global provider of bio-based pest management and plant health products, announced it has submitted MBI-302, a biological nematicide, for registration with the United States EPA. The product utilizes a new patent-pending species of bacteria, Flavobacterium sp. strain H492, discovered in MBI's discovery screen for suppression of nematodes in agricultural and horticultural crops. It is active against a broad range of plant parasitic nematode species. Field trials conducted in 2013 show that MBI-302, when applied as a seed treatment, reduced soybean cyst nematode numbers and enhanced soybean yields. MBI is developing the product as a seed treatment and as a liquid to be applied via broadcast, in-furrow, shank, banded or chemigation methods.
"MBI's strategy is to develop multiple products across all categories of growers' needs. MBI-302 nematicide joins MBI's fungicides, insecticides and herbicides to do just that," said CEO Pam Marrone.
The Society of Nematologists projects global crop losses due to plant parasitic nematodes at $100 billion each year. In the US alone, nematode damage to major crops, such as soybean, cotton, sugar beets, tomatoes, and many other fruits and vegetables is estimated to reduce crop yields by more than $5 billion annually. AVRDC (The World Vegetable Center) estimates losses in vegetables range from 17–38 percent. With many chemical pesticides restricted or eliminated due to their toxicity to mammals and other organisms, biological nematicides can provide an effective, more sustainable solution.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (NASDAQ: MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental, and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements relating to market size and the results from the field trials. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the in the Form 10-Q that the Company filed with the Securities and Exchange Commission on November 8. 2013.
SOURCE Marrone Bio Innovations, Inc.